Search research articles
Contact Us
Filters
Showing results (1-10 of 243) with videos related to
Page
of 25
Sort By:
Leukemia & Lymphoma
|
March 23, 2013
The potential of serum light chains in diffuse large B-cell lymphoma
Matthew J Maurer
Blood
|
September 7, 2019
POD24 in MZL: a means to an end or an end point in itself?
Matthew J Maurer
Haematologica
|
November 2, 2023
The International Prognostic Index in aggressive B-cell lymphoma
Matthew J Maurer
British Journal of Haematology
|
April 14, 2021
Reversing the restrictive trend in diffuse large B-cell lymphoma trial eligibility: it's time to open the gates!
Arushi Khurana, Matthew J Maurer
Blood
|
February 28, 2025
End points and Outcomes in Follicular Lymphoma: What should we measure, how, and why?
Mengyang Di, Matthew J Maurer, Christopher R Flowers
Methods in Molecular Biology (Clifton, N.J.)
|
August 6, 2013
Survival prediction based on inherited gene variation analysis
Mine S Cicek, Matthew J Maurer, Ellen L Goode
The Journal of Biological Chemistry
|
September 25, 2008
Degradation of a cytosolic protein requires endoplasmic reticulum-associated degradation machinery
Meredith Boyle Metzger, Matthew J Maurer, Beverley M Dancy, et al.
American Journal of Hematology
|
October 17, 2022
Utilization of real-world data in assessing treatment effectiveness for diffuse large B-cell lymphoma
Grzegorz Nowakowski, Matthew J Maurer, James R Cerhan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 25, 2015
Reply to V. Pitini et al and L.J. Costa
Carrie A Thompson, Herve Ghesquieres, Matthew J Maurer, et al.
Blood Cancer Journal
|
March 13, 2021
JAK2 activation promotes tumorigenesis in ALK-negative anaplastic large cell lymphoma via regulating oncogenic STAT1-PVT1 lncRNA axis
Kang Le, Linda E Wellik, Matthew J Maurer, et al.
Page
of 25
Search research articles
Search
Showing results (1-10 of 243) with videos related to
Sort By:
Page
of 25
Leukemia & Lymphoma
|
March 23, 2013
The potential of serum light chains in diffuse large B-cell lymphoma
Matthew J Maurer
Blood
|
September 7, 2019
POD24 in MZL: a means to an end or an end point in itself?
Matthew J Maurer
Haematologica
|
November 2, 2023
The International Prognostic Index in aggressive B-cell lymphoma
Matthew J Maurer
British Journal of Haematology
|
April 14, 2021
Reversing the restrictive trend in diffuse large B-cell lymphoma trial eligibility: it's time to open the gates!
Arushi Khurana, Matthew J Maurer
Blood
|
February 28, 2025
End points and Outcomes in Follicular Lymphoma: What should we measure, how, and why?
Mengyang Di, Matthew J Maurer, Christopher R Flowers
Methods in Molecular Biology (Clifton, N.J.)
|
August 6, 2013
Survival prediction based on inherited gene variation analysis
Mine S Cicek, Matthew J Maurer, Ellen L Goode
The Journal of Biological Chemistry
|
September 25, 2008
Degradation of a cytosolic protein requires endoplasmic reticulum-associated degradation machinery
Meredith Boyle Metzger, Matthew J Maurer, Beverley M Dancy, et al.
American Journal of Hematology
|
October 17, 2022
Utilization of real-world data in assessing treatment effectiveness for diffuse large B-cell lymphoma
Grzegorz Nowakowski, Matthew J Maurer, James R Cerhan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 25, 2015
Reply to V. Pitini et al and L.J. Costa
Carrie A Thompson, Herve Ghesquieres, Matthew J Maurer, et al.
Blood Cancer Journal
|
March 13, 2021
JAK2 activation promotes tumorigenesis in ALK-negative anaplastic large cell lymphoma via regulating oncogenic STAT1-PVT1 lncRNA axis
Kang Le, Linda E Wellik, Matthew J Maurer, et al.
Page
of 25